Page 25 - 84_04

Arantxa Rodriguez-Casado, Adolfo Toledano-Díaz, María-Isabel Álvarez, Adolfo Toledano
Obesidad: ¿un riesgo para la enfermedad de
Alzheimer?. I. Mecanismos Moleculares comunes. An
Real Acad Farm 2016; 82:303-316.
2. Zhang PY. Cardiovascular disease in diabetes. Eur Rev
Med Pharmacol Sci 2014;18(15):2205-14.
3. Ghos S. Ectopic fat: The potential target for obesity
management. J Obes Metab Res 2014;1(1):30-8.
4. Smith U. Abdominal obesity: a marker of ectopic fat
accumulation. J Clin Invest 2015; 125(5):1790-2.
5. Hildreth KL, VanPelt RE, Schwartz RS. Obesity, insulin
resistance, and Alzheimer's disease. Obesity (Silver
Spring) 2012;20(8):1549-57.
6. Nuzzo D, Picone P, Baldassano S, Caruana L, Messina
E, Marino Gammazza A, et al. Insulin resistance as
common molecular denominator linking Obesity to
Alzheimer's Disease. Curr Alzheimer Res
2015;12(8):723-35.
7. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG.
Inflammation, defective insulin signaling, and
neuronal dysfunction in Alzheimer's disease.
Alzheimers Dement 2014;10(Suppl 1):S76-83.
8. DeFelice FG, Lourenco MV, Ferreira ST. How does
brain insulin resistance develop in Alzheimer's
disease? Alzheimers Dement 2014;10(Suppl 1):S26-
32.
9. De la Monte SM. Relationships between diabetes and
cognitive impairment. Endocrinol Metab Clin North
Am 2014;43(1):245-67.
10.De la Monte SM, Tong M. Brain metabolic dysfunction
at the core of Alzheimer's disease. Biochem
Pharmacol 2014;88(4):548-59.
11. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP,
Stucky A, et al. Demonstrated brain insulin resistance
in Alzheimer's disease patients is associated with IGF-
1 resistance, IRS-1 dysregulation, and cognitive
decline. J Clin Invest 2012;122(4):1316-38.
12. Esser N, Paquot N, Scheen AJ. Inflammatory markers
and cardiometabolic diseases. Acta Clin Belg
2015;70(3):193-9.
13. Heneka MT, Carson MJ, El Khoury J, Landreth GE,
Brosseron F, Feinstein DL, et al. Neuroinflammation
in Alzheimer's disease. Lancet Neurol
2015;14(4):388-405.
14. Craft S, Cholerton B, Baker LD. Insulin and
Alzheimer’s disease: untangling the web. J
Alzheimers Dis 2013;33(Suppl 1):S263-75.
15. Calay ES, Hotamisligil GS. Turning off the
inflammatory, but not the metabolic flames. Nat Med
2013;19(3):265-7.
16. Bomfim TR, Bomfim TR, Forny-Germano L, Sathler
LB, Brito-Moreira J, Houzel JC, et al. An anti-
diabetes agent protects the mouse brain from defective
insulin signaling caused by Alzheimer's disease-
associated Abeta oligomers. J Clin Invest
2012;122(4):1339-53.
17. Elwing JE, Lustman PJ, Wang HL, Clouse RE.
354 @Real Academia Nacional de Farmacia. Spain
Depression, anxiety, and nonalcoholic steatohepatitis.
Psychosom Med 2006;68(4):563-9.
18. Perry W, Hilsabeck RC, Hassanein TI. Cognitive
dysfunction in chronic hepatitis C: a review. Dig Dis
Sci 2008;53(2):307-21.
19. Tong M, Neusner A, Longato L, Lawton M, Wands
JR, de la Monte SM. Nitrosamine exposure causes
insulin resistance diseases: relevance to T2DM, non-
alcoholic steatohepatitis and Alzheimer disease. J
Alzheimers Dis 2009;17(4):827-44.
20. De la Monte SM Tong M, Lester-Coll N, Plater M Jr,
Wands JR.. Therapeutic rescue of neurodegeneration
in experimental type 3 diabetes: relevance to
Alzheimer's disease. J Alzheimers Dis 2006;10(1):89-
109.
21. Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E,
Longato L, Jiao P, et al. Hepatic ceramide may
mediate brain insulin resistance and
neurodegeneration in type 2 diabetes and non-
alcoholic steatohepatitis. J Alzheimers Dis
2009;16(4):715-29.
22 Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands
JR, de la Monte SM. Intracerebral streptozotocin
model of type 3 diabetes: relevance to sporadic
Alzheimer's disease. J Alzheimers Dis 2006;9(1):13-
33.
23.Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. J
Cell Mol Med 2011;15(9):1807-21.
24. Acharya NK, Levin EC, Clifford PM, Han M, et al.
Diabetes and hypercholesterolemia increase blood-
brain barrier permeability and brain amyloid
deposition: beneficial effects of the LpPLA2 inhibitor
darapladib. J Alzheimers Dis 2013;35(1):179-98.
25. Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE,
Reijerkerk A, King-Robson J, Kay O, et al.
MicroRNA-155 negatively affects blood-brain barrier
function during neuroinflammation. FASEB J
2014;28(6):2551-65.
26. Contreras C, González-García I, Martínez-Sánchez N,
Seoane-Collazo P, Jacas J, Morgan DA, et al. Central
ceramide-induced hypothalamic lipotoxicity and ER
stress regulate energy balance. Cell Rep
2014;9(1):366-77.
27. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H,
Morishita R. Increased blood-brain barrier
vulnerability to systemic inflammation in an
Alzheimer disease mouse model. Neurobiol Aging
2013;34(8):2064-70.
28. Capeau J. Insulin resistance and steatosis in humans.
Diabetes Metab 2008;34(6 Pt 2):649-57.
29. Gontier G, Lin K, Villeda SA. Fat Chance for Neural
Stem Cells in Alzheimer's Disease. Cell Stem Cell
2015;17(4):373-4.
30. Hamilton LK, Dufresne M, Joppé SE, Petryszyn S,
Aumont A, Calon F, et al. Aberrant Lipid Metabolism
in the Forebrain Niche Suppresses Adult Neural Stem
Cell Proliferation in an Animal Model of Alzheimer's